Caprock Group LLC Purchases 4,941 Shares of Johnson & Johnson (NYSE:JNJ)

Caprock Group LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 74,928 shares of the company's stock after acquiring an additional 4,941 shares during the quarter. Caprock Group LLC's holdings in Johnson & Johnson were worth $12,143,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Summit Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 0.6% during the second quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company's stock worth $1,463,000 after buying an additional 61 shares during the last quarter. Powers Advisory Group LLC grew its position in Johnson & Johnson by 0.6% during the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock worth $1,538,000 after acquiring an additional 61 shares during the last quarter. Citizens & Northern Corp increased its holdings in Johnson & Johnson by 3.5% in the 2nd quarter. Citizens & Northern Corp now owns 1,884 shares of the company's stock worth $275,000 after purchasing an additional 63 shares in the last quarter. Eagle Wealth Strategies LLC raised its position in Johnson & Johnson by 2.8% in the third quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company's stock valued at $372,000 after purchasing an additional 63 shares during the last quarter. Finally, Epic Trust Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 3.6% during the second quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company's stock valued at $268,000 after purchasing an additional 64 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Daiwa America lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 23rd. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, September 14th. Finally, Daiwa Capital Markets downgraded Johnson & Johnson from an "outperform" rating to a "neutral" rating and lowered their price objective for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Seven research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus price target of $175.94.

Johnson & Johnson Stock Down 1.2 %

JNJ stock traded down $1.80 during mid-day trading on Tuesday, reaching $152.97. 8,231,159 shares of the company traded hands, compared to its average volume of 7,024,149. The stock has a market cap of $368.29 billion, a price-to-earnings ratio of 22.14, a P/E/G ratio of 2.74 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The firm's 50 day moving average price is $160.83 and its 200 day moving average price is $156.19. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion for the quarter, compared to analysts' expectations of $22.17 billion. During the same period last year, the business earned $2.66 EPS. The business's revenue was up 5.2% on a year-over-year basis. As a group, equities research analysts predict that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.24%. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.